← Cancer trial database
Trial Spotlight
Non-small cell lung cancer

Phase 3 ABBV-1480 PD-1×VEGF bispecific antibody vs pembrolizumab in 1L sqNSCLC

Trial status

Currently Recruiting

Status as of

Got an update?
Trial ID
NCT07756645 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Registrational
Location
Fort Wayne, IN and Rio Piedras, PR (US, multi-center)
Published in
New in Oncology - Nov 19, 2026

AbbVie’s Phase 3, randomized, multiregional, open-label study tests whether ABBV-1480 plus platinum-doublet chemotherapy improves outcomes versus pembrolizumab (Merck’s PD-1 monoclonal antibody) plus the same chemotherapy in previously untreated, unresectable stage IIIB/IIIC or metastatic stage IV squamous NSCLC. ABBV-1480 (also known as RC148, licensed by AbbVie from RemeGen outside Greater China) is a PD-1/VEGF-directed bispecific designed to simultaneously release PD-1–mediated T-cell inhibition and block VEGF-driven angiogenesis and immune suppression in the tumor microenvironment. Participants receive IV ABBV-1480 + carboplatin (DNA crosslinking platinum) with paclitaxel or nab-paclitaxel (microtubule inhibitors), or IV pembrolizumab + the same chemo backbone. The key commercial/scientific angle is whether a single-molecule PD-1 + VEGF approach can outperform PD-1 + chemo without adding a separate anti-VEGF drug, in a setting where today’s care is pembrolizumab + carboplatin/taxane (or other PD-1/PD-L1 regimens) for eligible patients, with later-line options including docetaxel ± anti-angiogenic therapy and antibody-drug conjugates in selected contexts.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →